Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palisade Bio (PALI) Enterprise Value (2016 - 2025)

Palisade Bio has reported Enterprise Value over the past 16 years, most recently at -$132.4 million for Q4 2025.

  • Quarterly Enterprise Value fell 1256.13% to -$132.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$132.4 million through Dec 2025, down 1256.13% year-over-year, with the annual reading at -$132.4 million for FY2025, 1256.13% down from the prior year.
  • Enterprise Value was -$132.4 million for Q4 2025 at Palisade Bio, down from -$5.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$615000.0 in Q1 2021 and troughed at -$132.4 million in Q4 2025.
  • The 5-year median for Enterprise Value is -$11.3 million (2024), against an average of -$16.2 million.
  • The largest YoY upside for Enterprise Value was 93.87% in 2021 against a maximum downside of 1778.03% in 2021.
  • A 5-year view of Enterprise Value shows it stood at -$10.5 million in 2021, then dropped by 17.99% to -$12.4 million in 2022, then decreased by 0.4% to -$12.4 million in 2023, then increased by 21.47% to -$9.8 million in 2024, then crashed by 1256.13% to -$132.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Enterprise Value are -$132.4 million (Q4 2025), -$5.2 million (Q3 2025), and -$5.4 million (Q2 2025).